ADCT News
Archived Headlines
- Swiss oncology biotech ADC Therapeutics ups share offering by 40% ahead of $175 million US IPO 05/14/20
- Swiss oncology biotech ADC Therapeutics sets terms for $125 million US IPO 05/11/20
- US IPO Week Ahead: The IPO calendar is primed for a small pick-up 05/08/20
- The 2020 IPO market is now up 43% from its lows, a promising sign for May 04/28/20
- US IPO Weekly Recap: ORIC pops 61% and SPACs make a comeback 04/24/20
See more
US IPO Week Ahead: Biotechs break the post-election ice in a 3 IPO week
Updated Monday, 11/9. The US IPO market remains relatively quiet following election week, with three biotechs and one SPAC scheduled to raise $340 million in the week ahead. Oncology biotech IN8bio (INAB) plans to raise $75...read more
2020 biotech IPOs now average an 80% return from their offer price
The 2020 US biotech IPO class closed Wednesday with an 80% average return from the offering price, a historic run-up for the year's 23 development-stage drug developers. The group has averaged a 36% pop on day one, and then 35% from there. Biotechs make up 70%...read more
US IPO Weekly Recap: Filing activity pops in a 1 IPO week
One biotech and three SPACs went public this past week as the IPO market shows more signs of opening up. The VIX volatility index is hovering around 30, the IPO index is now up 58% from its March lows, and eight companies submitted initial filings, the most...read more
ADC Therapeutics prices upsized IPO at $19, above the range
ADC Therapeutics, a Swiss Phase 2 biotech developing next-gen antibody drug conjugates for difficult-to-treat cancers, raised $233 million by offering 12.2 million shares at $19, above the range of $16 to $18. The company had originally filed to sell 7.4 million...read more